A Relative Bioavailability Study of Revatio for the Crushed Tablets, Extemporaneously Prepared Formulation, and the Intact Tablets at 20 mg Dose in Healthy Volunteers

NCT01027117 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Revatio
DRUG: Revatio
DRUG: Revatio

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.